Grant: Project Grant - Priority Announcement: Early Detection/Cancer Prevention
McGill University
$100,000.00
A prospective study of risk stratification with epigenetic markers to improve clinical management of cervical precancerous lesions
FY 2024-25
Summary
Cervical cancer screening is gradually changing from the 70-year-old Pap test to molecular testing for the human papillomavirus (HPV) that is present in uterine cervix cells as cause of this disease. Other than knowledge of the HPV type and patient's age, which provide incomplete prediction, there is little than can help clinicians in tailoring management for patients with cervical pre-cancer. It has been demonstrated that natural epigenetic changes (not changes in the DNA, instead they simply change how a cell reads the DNA) are necessary for a cervical precancerous lesion to develop into cervical cancer.
The proposed research couples cutting-edge molecular testing to the practical approach of self-samples in cervical cancer screening. We will conduct a study in colposcopy clinics to evaluate the prospective prognostic potential of newly discovered and validated methylation markers in a cohort study with new patients. We will determine the risk of progression of low- and high- grade cervical precancerous lesions. This could influence clinical management of women with cervical precancerous lesions to determine if more aggressive follow-up or treatment is needed considering their propensity to progress to cancer. Specifically, we will characterize the methylation profile of physician-collected (at all study visits) and self-collected (only at first visit) specimens and correlate them with disease progression from normal through precancerous lesions.
Findings may translate into new assays for physician-collected and self-samples to be used in monitoring screened patients' risk of progression to cervical cancer via utilization of a high-precision risk prediction.
Department
Program
Project Grant - Priority Announcement: Early Detection/Cancer Prevention
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
514255
Name
Koushik Anita
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Public, Community & Population Health 2
Projecttitle
A prospective study of risk stratification with epigenetic markers to improve clinical management of cervical precancerous lesions
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Early Detection/Cancer Prevention
Keyworddelim
Cervical Cancer; Cervical Intraepithelial Neoplasia; Dna Methylation; Human Papillomavirus; Risk Stratification; Self-Sampling
Abstract
Cervical cancer screening is gradually changing from the 70-year-old Pap test to molecular testing for the human papillomavirus (HPV) that is present in uterine cervix cells as cause of this disease. Other than knowledge of the HPV type and patient's age, which provide incomplete prediction, there is little than can help clinicians in tailoring management for patients with cervical pre-cancer. It has been demonstrated that natural epigenetic changes (not changes in the DNA, instead they simply change how a cell reads the DNA) are necessary for a cervical precancerous lesion to develop into cervical cancer.
The proposed research couples cutting-edge molecular testing to the practical approach of self-samples in cervical cancer screening. We will conduct a study in colposcopy clinics to evaluate the prospective prognostic potential of newly discovered and validated methylation markers in a cohort study with new patients. We will determine the risk of progression of low- and high- grade cervical precancerous lesions. This could influence clinical management of women with cervical precancerous lesions to determine if more aggressive follow-up or treatment is needed considering their propensity to progress to cancer. Specifically, we will characterize the methylation profile of physician-collected (at all study visits) and self-collected (only at first visit) specimens and correlate them with disease progression from normal through precancerous lesions.
Findings may translate into new assays for physician-collected and self-samples to be used in monitoring screened patients' risk of progression to cervical cancer via utilization of a high-precision risk prediction.
Competitiondate
202409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Koushik, Anita; Franco, Eduardo L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~